Compare CTRA & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRA | INSM |
|---|---|---|
| Founded | 1989 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7B | 22.5B |
| IPO Year | 1994 | 2000 |
| Metric | CTRA | INSM |
|---|---|---|
| Price | $32.77 | $107.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 24 |
| Target Price | $35.06 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 6.9M | 3.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 49.33 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $7,645,000,000.00 | N/A |
| Revenue This Year | $15.95 | $182.31 |
| Revenue Next Year | $6.22 | $65.19 |
| P/E Ratio | $53.72 | ★ N/A |
| Revenue Growth | ★ 40.07 | N/A |
| 52 Week Low | $22.33 | $64.85 |
| 52 Week High | $36.88 | $212.75 |
| Indicator | CTRA | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 32.44 |
| Support Level | $23.04 | $98.90 |
| Resistance Level | $36.88 | $166.81 |
| Average True Range (ATR) | 0.98 | 7.83 |
| MACD | 0.08 | -1.55 |
| Stochastic Oscillator | 49.21 | 17.77 |
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.